Nanoscale, Год журнала: 2023, Номер 15(44), С. 17839 - 17849
Опубликована: Янв. 1, 2023
The selected sponge medium that can be used in concurrent TTFields and radiotherapy for GBMs exhibits almost no negative impact on dosimetry CT imaging, corroborating its great viability safety clinical applications.
Язык: Английский
Brain Sciences, Год журнала: 2023, Номер 13(11), С. 1536 - 1536
Опубликована: Окт. 31, 2023
Glioblastoma multiforme (GBM) is a primary malignant brain tumor characterized by high grade of malignancy and an extremely unfavorable prognosis. The current efficacy established treatments for GBM insufficient, necessitating the prompt development novel therapeutic approaches. progress made in fundamental scientific understanding swiftly translated into more advanced stages studies. Despite extensive efforts to identify new approaches, exhibits mortality rate. patients insufficient due factors such as heterogeneity, blood–brain barrier, glioma stem cells, drug efflux pumps, DNA damage repair mechanisms. Considering this, pharmacological cocktail therapy has demonstrated growing addressing these challenges. Towards various forms immunotherapy, including immune checkpoint blockade, chimeric antigen receptor T (CAR T) cell therapy, oncolytic virotherapy, vaccine have emerged potential strategies enhancing prognosis GBM. Current investigations are focused on exploring combination therapies mitigate undesirable side effects enhance responses against tumors. Furthermore, clinical trials underway evaluate several circumvent barrier (BBB) achieve targeted delivery suffering from recurrent In this review, we described biological molecular targets pharmacologic status, prominent resistance mechanisms, treatment We also discuss promising approaches assess prospective innovative agents evaluated present state preclinical studies treatment. Overall, review attempts provide comprehensive information status therapy.
Язык: Английский
Процитировано
86
Cells, Год журнала: 2024, Номер 13(4), С. 336 - 336
Опубликована: Фев. 13, 2024
Glioblastoma (GB) is a rare but extremely aggressive brain tumor that significantly impacts patient outcomes, affecting both duration and quality of life. The protocol established by Stupp colleagues in 2005, based on radiotherapy chemotherapy with Temozolomide, following maximum safe surgical resection remains the gold standard for GB treatment; however, it evident nowadays extreme intratumoral intertumoral heterogeneity, as well invasiveness tendency to recur, are not compatible routine unfortunately ineffective treatment. This review article summarizes main challenges search new valuable therapies focuses impact extracellular vesicle (EV) research exploitation may have field. EVs natural particles delimited lipidic bilayer filled functional cellular content released uptaken cells key means cell communication. Furthermore, stable body fluids tolerated immune system, able cross physiological, interspecies, interkingdom barriers target specific cells, releasing inherent or externally loaded functionally active molecules. Therefore, potential be ideal allies fight against improve prognosis patients. present work describes preclinical results obtained so far use treatment, focusing EV sources molecular cargo used various studies, primarily vivo. Finally, SWOT analysis performed, highlighting advantages pitfalls developing EV-based therapeutic strategies. also suggests directions explore realize possibility exploiting treatment GB.
Язык: Английский
Процитировано
8
Colloids and Surfaces B Biointerfaces, Год журнала: 2024, Номер 245, С. 114258 - 114258
Опубликована: Сен. 19, 2024
Язык: Английский
Процитировано
7
International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(6), С. 3415 - 3415
Опубликована: Март 18, 2024
Glioblastoma multiforme (GBM) is a malignancy of bad prognosis, and advances in early detection treatment are needed. GBM heterogenous, with varieties differing within tumor patient between patients. Means needed to distinguish these GMB forms, so that specific strategies can be deployed for management. We study the participation chaperone system (CS) carcinogenesis. The CS dynamic, its members moving around body extracellular vesicles (EVs) interacting components other physiological systems health disease, including GBM. Here, we describe finding high amounts Hsp70 (HSPA1A) calcitonin receptor protein (CTR) EVs patients present standardized protocol collecting, purifying, characterizing carrying CTR plasma-derived from were obtained just before ablative surgery (T0) 7 days afterwards (T1); was highly elevated at T0 less T1, greatly increased reduced below normal values T1. Our results encourage further research assess as biomarkers differentiating forms determine their roles
Язык: Английский
Процитировано
6
Soft Matter, Год журнала: 2024, Номер 20(23), С. 4524 - 4543
Опубликована: Янв. 1, 2024
The goal of this review is to present enzymosomes as an innovative means for site-specific drug delivery.
Язык: Английский
Процитировано
4
Materials Today Bio, Год журнала: 2024, Номер 29, С. 101283 - 101283
Опубликована: Окт. 1, 2024
Язык: Английский
Процитировано
3
Cureus, Год журнала: 2025, Номер unknown
Опубликована: Март 7, 2025
Background: Angiopoietin-2 (ANGPT2) and cell migration-inducing protein (CEMIP) are key regulators of angiogenesis, extracellular matrix remodeling, metastatic progression in various cancers, including lung cancer (LC). The presence these biomarkers vesicles (EVs) may offer valuable insights into the molecular mechanisms underlying LC metastasis. Extracellular play a critical role by enhancing intercellular communication supporting processes such as immune evasion, metastasis, transferring molecules like vascular endothelial growth factor (VEGF) pro-angiogenic microRNAs (miRNAs). Methods: This study aimed to investigate quantification ANGPT2 CEMIP cargo EVs isolated from plasma samples obtained peripheral venous blood patients with localized (LLC group), brain metastases (LCM healthy controls (HC group). were using density gradient ultracentrifugation method, their characterization was performed through scanning transmission electron microscopy well flow cytometry. Western blot analysis used identify EV cargo, band intensity western images quantified specialized software. Results: expression significantly higher oncologic groups LCM combined) compared HC group. Notably, levels were, on average, 59% than those cancer. Following surgical resection, postoperative decreased 36% 8.5%, respectively, LLC group, 40% 4.6%, Conclusion: These findings emphasize potential for prognosis. To our knowledge, no previous has evaluated patients. further validate progression, functional studies should explore mechanistic effects EV-associated modulation, migration, tumor models.
Язык: Английский
Процитировано
0
Molecular Pharmaceutics, Год журнала: 2025, Номер unknown
Опубликована: Март 26, 2025
Glioblastoma (GBM) is a highly aggressive brain tumor with resistance to conventional therapies. Mithramycin (Mit-A), potent antitumor agent, has shown promise in several types including, GBM. However, its clinical application limited by toxicity. To address this, we explored the use of milk-derived extracellular vesicles (mEVs) as delivery system enhance therapeutic efficacy Mit-A. In this study, mEVs were isolated using 3000 PEG precipitation method and confirmed their size, morphology, stability through dynamic light scattering (DLS), transmission electron microscopy (TEM), atomic force (AFM). The size 125.6 ± 2.78 nm, polydispersity index (PDI) 0.083 0.02, ζ-potential 15 0.57 mV. presence typical EV markers such TSG101, HSP70, CD63 purity. Encapsulation Mit-A within led slight increase 131.8 6.9 PDI 0.081 0.006, decrease −17 2.0 mV, an encapsulation efficiency 58% freeze–thaw method. vitro transepithelial transport assay revealed that mEV(Mit-A) transported more effectively than free formulation demonstrated excellent simulated salivary gastrointestinal fluids, sustained release observed over 24 h PBS (pH 6.8). Furthermore, formulations significantly inhibited glioma cell growth, migration, induced apoptosis, showing 2-fold lower IC50 Mit-A, indicating superior efficacy. These findings suggest represent promising vehicle for enhancing potential effective treatment glioblastoma.
Язык: Английский
Процитировано
0
ACS Applied Bio Materials, Год журнала: 2025, Номер unknown
Опубликована: Май 12, 2025
RNA interference (RNAi) has emerged as a transformative approach for cancer therapy, enabling precise gene silencing through small interfering (siRNA). However, the clinical application of siRNA-based treatments faces challenges such rapid degradation, inefficient cellular uptake, and immune system clearance. Nanotechnology-enhanced siRNA delivery revolutionized therapy by addressing these limitations, improving stability, tumor-specific targeting, therapeutic efficacy. Recent advancements in nanocarrier engineering have introduced innovative strategies to enhance safety precision therapies, offering new opportunities personalized medicine. This review highlights three key innovations nanotechnology-enhanced delivery: artificial intelligence (AI)-driven design, multifunctional nanoparticles combined strategies, biomimetic nanocarriers enhanced biocompatibility. AI-driven utilize machine learning algorithms optimize nanoparticle properties, drug release profiles minimizing off-target effects. Multifunctional integrate with chemotherapy, immunotherapy, or photothermal synergistic treatment approaches that outcomes reduce resistance. Biomimetic nanocarriers, including exosome-mimicking systems cell-membrane-coated nanoparticles, improve circulation time, evasion, targeted tumor delivery. These collectively precision, efficiency, therapies. The scope novelty lie their ability overcome primary barriers while paving way clinically viable solutions. provides comprehensive analysis latest developments fabrication, preclinical studies, assessments. By integrating multifunctionality, biomimicry, holds immense potential future therapy.
Язык: Английский
Процитировано
0
Drug Delivery, Год журнала: 2024, Номер 31(1)
Опубликована: Июнь 4, 2024
With the rapid development of drug delivery systems, extracellular vesicles (EVs) have emerged as promising stars for improving targeting abilities and realizing effective delivery. Numerous studies shown when compared to conventional strategies in targeted (TDD), EVs-based several distinguished advantages besides targeting, such participating cell-to-cell communications immune response, showing high biocompatibility stability, penetrating through biological barriers, etc. In this review, we mainly focus on mass production EVs including challenges scaling up a cost-effective reproducible manner, loading active methods, examples vehicles TDD consideration potential safety regulatory issues associated. We also conclude discuss rigor reproducibility production, current research status application delivery, clinical conversion prospects, existing chances challenges.
Язык: Английский
Процитировано
3